The comparative pharmacokinetics and gastric toxicity of bezafibrate and ciprofibrate in the rat

References

• Abshagen U., Bablock W., Koch K., Lang P. D., Schmidt H. A. E., Senn M., Stork H. The metabolism and disposition of bezafibrate in normal volunteers. European Journal of Clinical Pharmacology 1979; 16: 31–38
   PubMed Web of Science ®Google Scholar
• Arnold A., McAuliff J. P., Powers L. G., Phillips D. K., Beyler A. L. The results of animal studies with ciprofibrate a new oral effective hypolipidaemic drug. Atherosclerosis 1979; 32: 155–163
   PubMed Web of Science ®Google Scholar
• Betton G. R., Dormer C. S., Wells T., Pert P., Price C. A., Buckley P. Gastric ECL cell hyperplasia and carcinoids in rodents following chronic administration of H2-antagonists SK and F 93479, oxmetidine and omeprazole. Toxicologic Pathology 1988; 16(2)288–298
   PubMed Web of Science ®Google Scholar
• Blom H. Alterations in gastric mucosal morphology induced by long term treatment with omeprazole in rats. Digestion 1986; 35(1)98–105
   PubMedGoogle Scholar
• Blane G. F., Pinarol F. Fenofibrate; etudes de toxicologie animale en rapport avec les effects secondaires chez les malades. Nouvelle Presse Medicale 1980; 949: 3737–3746
   Google Scholar
• Brittain R. T., Jack D., Reeves J., Stables R. Pharmacological basis for the induction of gastric carcinoid tumours in the rat by loxtidine, an unsurmountable histamine H2-receptor blocking drug. British Journal of Pharmacology 1985; 85: 843–847
   PubMed Web of Science ®Google Scholar
• Brodie R. R., Chasseaud L. F., Elsom F. F., Franklin E. R., Taylor T. The metabolic fate of the hypolipidaemic agent isopropyl-‘4′-(p-chlorobenzoyl’-2-phenoxy-2-methyl’propionic acid (CF 178) in rats, dogs and man. Arzneimittel-Forschung. Drug Research 1976; 26(5)896–901
   PubMed Web of Science ®Google Scholar
• Carlsson E., Larsson H., Mattsson H., Ryberg B., Sundell G. Pharmacology and toxicology of omeprazole with special reference to the effects on the gastric mucosa. Scandinavian Journal of Gastroenterology 1986; 21: 31–39
   PubMed Web of Science ®Google Scholar
• Cayen M. N. Metabolic disposition of antihyperlipidaemic agents in man and laboratory animals. Drug Metabolism Reviews 1980; 11(2)291–323
   PubMed Web of Science ®Google Scholar
• Cayen M. N. Metabolic and pharmacokinetics of antiphyperlipidaemic agents. Progress in Drug Metabolism Reviews, J. W. Bridges, L. F. Chasseaud. John Wiley & Sons Ltd, London 1983; Vol. 7: 173–227
   Google Scholar
• Clark B., Smith D. A. Pharmacokinetics and toxicity testing. Critical Reviews in Toxicology 1984; 12: 343–385
   PubMed Web of Science ®Google Scholar
• Clarke A. J., Clark B., Eason C. T., Parke D. V. An assessment of a toxicological incident in a drug development program and its implications. Regulatory Toxicology and Pharmacology 1985; 5: 109–119
   PubMed Web of Science ®Google Scholar
• Cohen A. J., Grasso P. Review of hepatic response to hypolipidaemic drugs in rodents and assessment of its toxicological significance to man. Food and Cosmetics Toxicology 1981; 19: 585–605
   PubMedGoogle Scholar
• Daly M. J., Pottage A. Antisecretory drugs and gastric cancer. British Medical Journal 1985; 291: 1646–1647
   PubMedGoogle Scholar
• Davies D. S. An introduction to metabolic and kinetic aspects of toxicology studies. Xenobiotica 1988; 18(1)3–7
   PubMedGoogle Scholar
• Davison C., Benziger D., Fritz A., Edelson J. Absorption and disposition of 2-‘4-(2,2-dichlorocyclopropyl)phenoxy’-2-methyl-propionic acid, WIN 35833, in rats, monkeys and man. Drug Metabolism and Disposition 1975; 3(6)520–524
   PubMed Web of Science ®Google Scholar
• Eason C. T., Spencer A. J., Pattison A., Howells D. D., Henry D. C., Bonner F. W. The toxicological consequences of the gastric antisecretory activity of ciprofibrate in the rat. Human Toxicology 1988a; 7(2)222–223
   Google Scholar
• Eason C. T., Pattison A., Howells D. D., Bonner F. W. The effect of ciprofibrate on gastric secretion in the rat. Journal of Pharmacy and Pharmacology 1988b; 40: 512–513
   PubMed Web of Science ®Google Scholar
• Eason C. T., Pattison A., Howells D. D., Spencer A. J., Bonner F. W. Assessment of gastric anti-secretory effects of phenoxyisobutyrate derivatives in rat and mouse. Scandinavian Journal of Gastroenterology 1988c, (In press)
   PubMed Web of Science ®Google Scholar
• Eason C. T., Spencer A. J., Pattison A., Howells D. D., Henry D. C., Bonner F. W. Species variation in gastric toxicity following chronic administration of ciprofibrate to rat, mouse and marmoset. Toxicology and Applied Pharmacology 1988d; 95: 328–338
   PubMed Web of Science ®Google Scholar
• Eason C. T., Parke D. V., Clark B., Smith D. A. The mechanism of hepatotoxicity of a chromone carboxylic acid (FPL 52757) in the dog. Xenobiotica 1982; 12: 155–164
   PubMed Web of Science ®Google Scholar
• Edelson J., Benziger D. P., Arnold A., Beyler A. L. Blood levels, tissue distribution and the duration of action in rats of ciprofibrate, a new hypolipidaemic agent. Atherosclerosis 1979; 33(3)351–357
   PubMed Web of Science ®Google Scholar
• Ekman L., Hansson E., Havu H., Carlsson E., Lundberg G. Toxicology studies on omeprazole. Scandinavian Journal of Gastroenterology 1985; 20(Suppl. 108)53–69
   Google Scholar
• Elder J. B. Inhibition of acid and gastric carcinoids. Gut 1986; 26: 1279–1283
   Web of Science ®Google Scholar
• Gibaldi M. Non-compartmental pharmacokinetics. Biopharmaceuticals and clinical pharmacokinetics, 3rd edn. Lee & Febiger, Philadelphia 1984; 26–27
   Google Scholar
• Hakanson R., Bottcher G., Ekblad E., Panula P., Simonsson M., Dohlsten M., Hallberg T., Sundler F. Histamine in endocrine cells in the stomach. Histochemistry 1986; 86: 5–17
   PubMedGoogle Scholar
• Illingworth D. R., Olsson G. D., Cook S. F., Sexton G. J., Wendel H. A., Conner W. E. Ciprofibrate in therapy of type II hypercholesterolaemia, a double-blind trial. Atherosclerosis 1982; 44: 211–221
   PubMed Web of Science ®Google Scholar
• Langman M. J. S. Antisecretory drugs and gastric cancer. British Medical Journal 1985; 290: 1850–1853
   PubMedGoogle Scholar
• Larsson H., Carlsson E., Mattsson H., Lundell L., Sundler F., Sundell G., Wallmark B., Watanabe T., Hakanson R. Plasma gastrin and gastric enterochromaffin like cell activation and proliferation. Gastroenterolgy 1986; 90: 391–399
   PubMed Web of Science ®Google Scholar
• Lippmann W., Seethaler K. J. Clofibrate: antisecretory antiulcer activity in the rat. Journal of Pharmacy and Pharmacology 1976; 28: 165–166
   PubMed Web of Science ®Google Scholar
• Nau H. Teratogenic valproic acid concentrations: Infusions by implanted minipumps vs conventional injection regimes in the mouse. Toxicology and Applied Pharmacology 1985; 80: 243–250, OECD guidelines for testing of chemicals
   PubMed Web of Science ®Google Scholar
• Pattison A., Eason C. T., Bonner F. W. Species variation in plasma gastrin levels. Medical Science Research 1987; 15: 233–234
   Google Scholar
• Poynter D., Pick C. R., Harcourt R. A., Selway S. A. M., Ainge G., Harman I. W., Spurling N. W., Fluck P. A., Cook J. L. Association of long-lasting unsurmountable histamine H2-blockage and gastric carcinoid tumours in the rat. Gut 1985; 26: 1284–1295
   PubMed Web of Science ®Google Scholar
• Poynter D., Selway S. A. M., Papworth S. A., Kiches S. R. Changes in the gastric mucosa of the mouse associated with long-lasting insurmountable histamine H2 blockade. Gut 1986; 27(11)1338–1346
   PubMed Web of Science ®Google Scholar
• Rheault M. J., Laberge M., Lelomer J., Tetreault C. The gastric antisecretory effects of clofibrate in the rat. Revue Canadienne de Biologie Experimentale 1982; 41: 165–168
   PubMedGoogle Scholar
• Schmidt F. H., Stegmeier K., Stork H., Endele R., Koche K. Pharmacokinetics and metabolism of bezafibrate in animals. Lipoproteins and Coronary Heart Disease, H. Gretan, P. Lang, G. Schettler. Gerhard Witzstrock, New York 1979; 102–105
   Google Scholar
• Svoboda D. J., Azarnoff D. L. Tumours in male rats fed ethyl chlorophenoxyisobutyrate, a hypolipidaemic drug. Cancer Research 1979; 39: 3419–3428
   PubMed Web of Science ®Google Scholar
• Zbinden G. Biopharmaceutical studies, a key to better toxicology. Xenobiotica 1988; 18(1)9–14
   PubMedGoogle Scholar